Merck Serono

Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment

Retrieved on: 
måndag, juni 3, 2024
Research, Medical Devices, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, ADP, ASCO, PARP1, Cancer, CEACAM5, Merck Serono, Ovarian cancer, Glioblastoma, ATR, Merck, AACR, Health care, GD2, Patient, Cell, NSCLC, PARP, Society, ADC, DNA, Merck Group, Cell death, Niraparib, Ataxia–telangiectasia, Colorectal cancer, Carcinoma, Clinical trial, Neuroblastoma, Development, Osteosarcoma, Cell membrane, Lung cancer, ATM, DDR, Neoplasm, Part, Antigen, Prevalence, Avelumab, Phase, Pharmaceutical industry

“The advancements in our strong early-stage clinical pipeline of ADCs created with our in-house platform and DDR inhibitors are grounded in encouraging data, particularly for M9140 and tuvusertib.

Key Points: 
  • “The advancements in our strong early-stage clinical pipeline of ADCs created with our in-house platform and DDR inhibitors are grounded in encouraging data, particularly for M9140 and tuvusertib.
  • At Merck KGaA, Darmstadt, Germany, we strive every day to improve the futures of people living with cancer.
  • Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core.
  • Our vision is to create a world where more cancer patients will become cancer survivors.

Lantheus Announces Executive Appointments to Accelerate Innovation

Retrieved on: 
onsdag, maj 15, 2024
Statistics, Neuroscience, Public key certificate, Organization, Health, Kyowa Kirin, Sorbonne University, AB, Molecular biology, University, Bristol Myers Squibb, Drug development, Merck Serono, MD, Research, CMO, LNTH, Mathematics, CSO, Drug discovery, Internal medicine, Therapy, Harvard University, Applied mathematics, Pharmacology, Pharmaceutical industry

BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Jeffrey S. Humphrey, MD has been appointed Chief Medical Officer (CMO) and Jean-Claude Provost, MD has been named Chief Science Officer (CSO), effective May 28, 2024.

Key Points: 
  • “Jeff’s clinical oncology expertise and leadership will bring immense value to Lantheus as we strengthen our position as the leading radiopharmaceutical-focused company through sustained innovation in diagnostics and therapeutics,” said Brian Markison, Chief Executive Officer, Lantheus.
  • “Jean-Claude’s deep radiopharmaceutical knowledge and experience with the Lantheus team will be invaluable in his new role as CSO, as we execute our business development strategy to enhance our pipeline and capabilities.
  • As CMO, he will oversee Lantheus’ research and development organization, including research and pharmaceutical development, regulatory affairs, clinical development, medical affairs, and isotope strategy.
  • Dr. Jean-Claude Provost, in his new CSO role, will support Lantheus’ business development activities to advance and enhance the Company’s pipeline and capabilities.

EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024

Retrieved on: 
torsdag, maj 23, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Dana–Farber Cancer Institute, Neck, Risk, Liver, Avelumab, DDR, Carcinoma, University of California, Health care, Abstract (summary), Survival, Cough, BSC, Merck Serono, CEACAM5, Head, Atri, ADC, Abstract, Phase II, Merck, ATM, Quality of life (healthcare), CRT, Phase, Neoplasm, Safety, Institute of Cancer Research, Cancer, ASCO, Society, IAP, BIRC, Antigen, Patient, Pharmacokinetics, ADP, DNA, PARP, Phases of clinical research, University, Merck Group, Death, Clinical trial, Brain, Chemoradiotherapy, Annual general meeting, Pharmaceutical industry

Data from 40 patients treated across seven dose levels in Part 1A of the study showed encouraging clinical activity and a manageable and predictable safety profile in this population.

Key Points: 
  • Data from 40 patients treated across seven dose levels in Part 1A of the study showed encouraging clinical activity and a manageable and predictable safety profile in this population.
  • New findings for tuvusertib, the lead oral ATRi asset from the company’s portfolio of DNA damage response (DDR) inhibitors (Abstracts 3018, 2612, 2614).
  • Data from the DDRiver™ Clinical Trials program highlight the potential of the investigational oral ataxia telangiectasia and RAD3-related inhibitor (ATRi) tuvusertib in various combinations across solid tumors.
  • Data show a manageable safety profile and preliminary efficacy in patients with advanced solid tumors, confirming suitability of this combination for further evaluation.

The Foundation for the National Institutes of Health Announces the Launch of a Public-Private Partnership to Accelerate ALS Diagnosis and Treatment

Retrieved on: 
tisdag, maj 21, 2024
Technology, Biotechnology, Health, Neurology, Pharmaceutical, Philanthropy, Research, Software, General Health, Health Technology, Foundation, Science, Data Management, Clinical Trials, Partnership, MPH, Bangladesh Technical Education Board, Patient, Biogen, Biomarker, Survival, Daniel L. Doctoroff, Hope, Critical Path Institute, NINDS, Risk, Food, Diagnosis, Depression, FDA, Lewy body dementias, Merck Serono, Disease, FNIH, Drug development, Anxiety, GSK, DSM-IV codes, Caregiver, ALL, AMP, Spinal cord, Movement, AbbVie, Brain, ALS Association, Eli Lilly, ALS Therapy Development Institute, Quality of life, Family, Access, NIH, Pharmaceutical industry

ALS is a progressive and ultimately fatal neurological disease with few treatment options and no cure yet.

Key Points: 
  • ALS is a progressive and ultimately fatal neurological disease with few treatment options and no cure yet.
  • AMP ALS is supported by a combined commitment of approximately $60 million.
  • Patients can’t wait, given the typical survival time of two to five years after diagnosis,” said Julie Gerberding, MD, MPH, President and CEO of the FNIH.
  • The data set that we are creating with AMP ALS will be the most comprehensive ever in ALS research.

Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update

Retrieved on: 
torsdag, maj 16, 2024
Biotechnology, Diabetes, Other Health, Health, Pharmaceutical, DSM-IV codes, Merck Serono, JPY, Serono, Sumitomo Pharma, NASH, EUR, Fatty liver disease, Merck, FY, Pharmaceutical industry

Thomas Kuhn, Chief Executive Officer of Poxel, stated: “TWYMEEG® continues to demonstrate its effectiveness through its steadily progressively increasing sales in Japan.

Key Points: 
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “TWYMEEG® continues to demonstrate its effectiveness through its steadily progressively increasing sales in Japan.
  • Beyond 2024, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.
  • Poxel reported EUR 449 thousand5 revenue for the quarter ended March 31, 2024, similar to the revenue reported during the corresponding period in 2023.
  • Revenue for the first quarter of 2024 reflects JPY 75.9 million (EUR 465 thousand2) of royalty revenue from Sumitomo Pharma, which represents 8% of TWYMEEG® net sales in Japan.

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts

Retrieved on: 
torsdag, april 25, 2024
Genetics, CMO, Doctor of Philosophy, Boston, Development, Novartis, Pfizer, Operating partner, Functional genomics, CSO, Genome, Associate, Drug discovery, SAB, AbbVie, Baxalta, EVP, GSK plc, Bristol Myers Squibb, GSK, Baylor College of Medicine, University, Harvard Medical School, Therapy, Biotechnology, Inflammation, Hospital, NIH, Michigan State University, Respiratory Medicine, Imperial College London, IPO, Rockefeller University, Spatial, MPH, Genomics, Atlas Venture, Merck Serono, Genentech, University of Birmingham, Senior, Society, Acquisition, Discovery, Sanofi, Baylor University

New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.

Key Points: 
  • New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.
  • The SAB is chaired by Prof. Jim Hughes, Scientific Founder and Non-Executive Director of Nucleome Therapeutics.
  • Dr Russell Greig, Non-Executive Chair of the Nucleome’s Board, said: “We are delighted to have appointed such esteemed experts to the Nucleome team.
  • Steve’s multifaceted background, spanning academia, industry and leadership roles, positions him as a key contributor to Nucleome’s Scientific Advisory Board.

Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release

Retrieved on: 
måndag, april 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical Trials, Other Health, USD, Patient, Adenosine, DSM-IV codes, ADPKD, Sumitomo Pharma, Safety, Pharmacokinetics, European Patent Convention, JPY, Merck Serono, Kidney, Male, Adrenoleukodystrophy, VLCFA, EUR, Plasma, Serono, Disease, NASH, Fatty liver disease, Patent, ALD, AMN, POC, Biomarker, Merck, EPO, Pharmaceutical industry

As a result, TWYMEEG gross sales should exceed its FY 2023 guidance of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan.

Key Points: 
  • As a result, TWYMEEG gross sales should exceed its FY 2023 guidance of JPY 4.2 billion (EUR 25.7 million)3 driven by a favourable sales trend in Japan.
  • Beyond 2024, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.
  • For territories not covered by its agreement with Sumitomo Pharma, Poxel is in ongoing discussions with potential partners for Imeglimin.
  • Net financial debt (excluding IFRS16 impacts and derivative debts) was EUR 47.4 million as of March 31, 2024, as compared to EUR 45.6 million as of December 31, 2023.

Amid threats to IVF, National Infertility Awareness Week® Brings Awareness Activities Across the Country

Retrieved on: 
måndag, april 15, 2024
CVS, Fertility, NIAW, Social media, Woman, Infertility, Human services, Merck Serono, Encompass, IVF, Family, Ferring Pharmaceuticals, Legislation, Movement, Face, First, The Cooper Companies, Birth control

MCLEAN, Va., April 15, 2024 /PRNewswire-PRWeb/ -- RESOLVE: The National Infertility Association (RESOLVE) will recognize National Infertility Awareness Week®, April 21 through April 27, 2024. The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families. RESOLVE will rally the infertility community to share their stories in an effort to raise awareness about the threats to family building options like IVF, the lack of access to family building options and the need for emotional support for the 1 in 6 people who will face infertility. #LeaveYourMark is a message found on the official NIAW website and throughout RESOLVE's social media campaigns.

Key Points: 
  • RESOLVE: The National Infertility Association will recognize National Infertility Awareness Week®, April 21 through April 27, 2024.
  • The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families.
  • MCLEAN, Va., April 15, 2024 /PRNewswire-PRWeb/ -- RESOLVE: The National Infertility Association (RESOLVE) will recognize National Infertility Awareness Week® , April 21 through April 27, 2024.
  • The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families.

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Retrieved on: 
torsdag, mars 21, 2024
University, Sanofi, Therapeutic index, Growth, GSK plc, Rotman School of Management, Merck Serono, Immunotherapy, Partnership, Patient, SAN, Ipsen, Merck, Cancer, Faculty, Society, TU Dresden, Therapy, Institute of technology, SITC, University of Florida

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.
  • “We are excited to welcome Zhen to our board,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.
  • Dr. Su is currently chief executive officer of Marengo Therapeutics and a member of its Board of Directors.
  • Dr. Su also serves on the board of directors of Karyopharm Therapeutics and as the funding chairperson for the biotech committee of the Society for Immunotherapy of Cancer (SITC).

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Retrieved on: 
onsdag, mars 13, 2024
Development, Gene editing, Growth, Regeneron Pharmaceuticals, Biotechnology, Science and nature, Merck Serono, Patient, Branches of microbiology, Acquisition, Virology, Executive Committee, Max Planck Society, CRISPR Therapeutics, University, Senior, Bayer, Publication, Therapy, Takeda, CRISPR, Amgen, CRSP, Medicine, Pharmaceutical industry

“We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.

Key Points: 
  • “We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.
  • Dr. Rommel currently serves as Executive Vice President, Global Head of Research & Development and a Member of the Executive Committee of Bayer Pharmaceuticals, Inc.
  • He joined Bayer from Roche, where he was most recently Senior Vice President, Global Head of Oncology, Pharma Research and Early Development (pRED).
  • He has authored more than 70 publications, including papers in Science and Nature, and is an inventor or co-inventor of 18 patents.